List of publication

  • Kon E, Hazan-Halevy I, Rosenblum D, Cohen N, Chatterjee S, Veiga N, Raanani P, Bairey O, Benjamini O, Nagler A, Peer D. Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics. 2020;12(6):E520.
  • Van de Vyver T, Bogaert B, De Backer L, Joris F, Guagliardo R, Van Hoeck J, Merckx P, Van Calenbergh S, Ramishetti S, Peer D, Remaut K, De Smedt SC, and Raemdonck K (2020) Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. ACS Nano. 14(4):4774-4791.
  • Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, Freilich I, Kolik Shmuel L, Danino D, and Peer D (2020) A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv Mater. 30:e1906128. (Cover)
  • Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y, and Peer D (2020) An Ovarian Spheroid Based Tumor Model that Represents Vascularized Tumors and Enables the Investigation of Nanomedicine Therapeutics. Nanoscale 23;12(3):1894-1903
  • Veiga N, Goldsmith M, Diesendruck Y, Ramishetti S, Rosenblum D, Elinav E, Behlke MA, Benhar I, and Peer D. (2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release. 313:33-41. (Cover)
  • Gao M, Deng J, Liu F, Fan A, Wang Y, Wu H, Ding D, Kong D, Wang Z, Peer D, and Zhao Y (2019) Triggered Ferroptotic Polymer Micelles for Reversing Multidrug Resistance to Chemotherapy. Biomaterials. 223:119486.
  • Hazan-Halevy I, Rosenblum D, Ramishetti S, and Peer D (2019) Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. Methods Mol Biol. 1974:151-159.
  • Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M1, Rizzuti I, Palomba R, Zunino P, Duocastella M4, Mizrahy S, Peer D, Decuzzi P (2019) A Tissue Chamber Chip for Assessing Nanoparticle Mobility in the Extravascular Space. Biomed Microdevices. 21(2):41.
  • Edri R, Gal I, Noor N, Harel T, Fleischer S, Adadi N, Green O, Shabat D, Heller L, Shapira A, Gat-Viks I, Peer D, and Dvir T (2019) Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. Adv Mater. 31(1):e1803895. (Cover)
  • Liu G, Deng J, Liu F, Wang Z, Peer D and Zhao Y (2018) Hierarchical Theranostic Nanomedicine: MRI Contrast Agents as a Physical Vehicle Anchor for High Drug Loading and Triggered on-demand Delivery. J. Mat. Chem. B 6:1995–2003.
  • Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, Ramishetti S, and Peer D (2018) Cell-Specific Delivery of Modified mRNA Expressing Therapeutic Proteins to Leukocytes. Nature Commun. 9(1):4493-449.
  • Goldsmith M, Abramovitz L, Braunstein H, Horowitz M, and Peer D (2018) Quantitative Analysis of Recombinant Glucocerebrosidase Brain Delivery via Lipid Nanoparticles. Nano Futures 2(4).
  • Kedmi R*, Veiga N*, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, and Peer D (2018) A Modular Platform for Targeted RNAi Therapeutics. Nature Nanotechnology 13(3):214-219. *denotes equal contribution
  • Karp J. M. and Peer D. (2018) Editorial: Focus on RNA interference: from nanoformulations to in vivo delivery. Nanotechnology 29(1):010201.
  • Zyuzin MV, Díez P, Goldsmith M, Carregal-Romero S, Teodosio C, Rejman J, FeliuN, Escudero A, Almendral MJ, Linne U, Peer D, Fuentes M, and Parak WJ (2017). Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. Bioconjug Chem.
  • Soffer-Tsur N., Peer D., and Dvir T (2016) ECM-based Macroporous Sponges Release Essential Factors to Support the Growth of Hematopoietic Cells. Journal of Controlled Release 257:84-90.
  • Kedmi R, and Peer D. (2016) Zooming in on Selectins in Cancer. Science. Transl. Med. 8(345):1-2. (Cover)
  • Weinstein S, Toker, IA, Emmanuel R, Ramishetti R, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abrahamc A, Benjamini B, Bairey O, Raanani R, Nagler A, Liebermane J and Peer D (2016) Harnessing RNAi Based-Nanomedicines for Therapeutic Gene Silencing in B cell Malignancies. Proc. Natl. Acad. Sci. USA 113(1) E16-E22.
  • Dearling, J, Daka, A, Veiga, N, Peer, D, and Packard A (2016) ImmunoPET of Colitis: Defining Target Cell Populations and Optimizing Pharmacokinetics. Inflammatory Bowel Diseases 22(3):529-538.
  • Ben-Arye T., Park S., Shemesh J., Peer D., Levenberg S. and Yossifon G (2015) Dielectrophoretic Characterization of Cells in a Stationary Nanoliter Droplet Array with Generated Chemical gradients. Biomed Microdevices 17: 91.
  • Ramishetti S*, Kedmi R*, Goldsmith M, Leonard F, Speague AG, Godin B, Gozin M, Cullis P, Dykxhoorn DM, and Peer D (2015) Systemic Gene Silencing in Primary T lymphocytes using Targeted Lipid Nanoparticles. ACS Nano 9(7):6706-6716 *denotes equal contribution.

Prof. Dan Peer

Curriculum Vitae

Experience

Founder and Chairman of the BoD

NeoVac

Chairman of the BoD

Ramot - Tel Aviv University's Tech Transfer Arm

Chairman of the BoD

TAU Ventures

Vice President for Research and Development

Tel Aviv University

Professor

Tel Aviv University

Managing Director, Center for Translational Medicine

Tel Aviv University

Vice President for Research and Development

Tel Aviv University

Chair, Cancer Biology Research Center

Tel Aviv University

Board Member

ART BioScience

Founder and member of the Board

SEPL Pharma

Founder and member of the Board

Quiet Therapeutics

Director

TAU Ventures

Director

Ramot at Tel Aviv University Ltd.

Member, Managing Board Member

Israel Young Academy

President

Israel chapter of the CRS

Founder

Leuko Bioscience

Research Fellow

CBR Institute (IDI) Harvard Medical

Research Fellow

Immune Disease Institute

Research Fellow

Harvard Medical School
Education

Harvard Medical School

Postdoc fellow

Tel Aviv University

Ph.D., Biochemistry / Biophysics
  • Activities and societies: AAPS - American association of pharmaceutical sciences - member, AACR - American association of cancer research - member, Harvard Stem Cell Institute - member, Biomatrix - Harvard / MIT division of Health, Science and Technology - Mentor

There is no clinical tryout at the moment of MuTaTo in Israel or outside of Israel.

Contact us at [email protected]

Contact Us

    Our team are research scientists (Ph.D.) and are not attending Dr.

    We are working now for the 20th year entering our 21th year of R&D effort (in June 2022).

    We don’t have a Clinique and we can not advise nor refer to any specific case.

    We initially intend to target: lung, colon, head & neck cancers.

    The treatment, in any case, has to be individually adapted to the patient.

    We are a small team and have an influx of e-mail.

    We try to answer at least initial emails but can not promise it.

    This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.